Article

The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial

IRCCS G, Gaslini and University of Genoa, Genoa, Italy. .
Pediatric Rheumatology (Impact Factor: 1.62). 09/2010; 8:24. DOI: 10.1186/1546-0096-8-24
Source: PubMed

ABSTRACT We evaluated the effect of infliximab on markers of inflammation in patients with juvenile idiopathic arthritis (JIA).
In this randomized, placebo-controlled substudy, 122 patients with JIA received infliximab 3 mg/kg + methotrexate (MTX)(n = 60) or placebo + MTX (n = 62) at weeks 0, 2, and 6. At week 14, patients receiving placebo + MTX crossed over to infliximab 6 mg/kg + MTX; patients receiving infliximab 3 mg/kg + MTX continued treatment through week 44. Sera and plasma from eligible patients receiving infliximab 3 mg/kg + MTX (n = 34) and receiving placebo→infliximab 6 mg/kg +MTX (n = 38) were collected at weeks 0, 2, 14, 16, 28, and 52 and analyzed for inflammatory markers (IL-6, IL-12p40, ICAM-1, MMP-3, VEGF, TNF-α, and CRP).
At week 2, decreases from baseline in IL-6, ICAM-1, MMP-3, TNF-α, and CRP were greater with infliximab versus placebo treatment, and with the exception of CRP, these differences were generally maintained through week 14. The decreases from baseline to week 52 in IL-6, ICAM-1, VEGF, MMP-3, and CRP and increases in IL-12p40 levels were larger in patients receiving placebo→infliximab 6 mg/kg +MTX versus infliximab 3 mg/kg + MTX treatment. Patients receiving infliximab 3 mg/kg+MTX who achieved an American College of Rheumatology Pediatric 30 (ACR-Pedi-30) response had significantly larger decreases from baseline in ICAM-1 (p = 0.0105) and MMP-3 (p = 0.0253) at week 2 and in ICAM-1 (p = 0.0304), MMP-3 (p = 0.0091), and CRP (p = 0.0011) at week 14 versus ACR-Pedi-30 nonresponders.
Infliximab + MTX attenuated several inflammatory markers in patients with JIA; larger decreases in ICAM-1, MMP-3, and CRP levels were observed in ACR-Pedi-30 responders versus nonresponders.
NCT00036374.

Download full-text

Full-text

Available from: Carrie Wagner, Aug 31, 2015
0 Followers
 · 
132 Views
 · 
37 Downloads
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this review we report an update on the current knowledge on growth disorders in children with chronic inflammatory diseases, mainly inflammatory bowel disease and juvenile idiopathic arthritis, with a particular focus on the role of inflammatory cytokines as mediators of growth impairment. Growth disorders are common among patients with inflammatory diseases. Several factors can contribute to growth failure: poor nutrition, immobilization, drugs, disease activity, duration and severity. There is extensive evidence suggesting that inflammatory cytokines are key players in mediating growth failure. Recent studies have confirmed a direct association between levels of inflammatory cytokines, such as tumour necrosis factor-α and interleukin-6, and reduced growth velocity, as well as impaired body composition. Recent studies have also highlighted the beneficial effect of new drugs, such biologics, not only in controlling disease activity, but also in improving growth. Growth retardation remains a major problem in patients with chronic inflammatory diseases, and proinflammatory cytokines are key players in this context. New drugs, specifically targeting inflammatory cytokines appear to be promising for their effect on growth. Further studies are required to better characterize the cytokine profile in children with inflammatory disease and help in developing effective treatment strategies.
    Current opinion in endocrinology, diabetes, and obesity 12/2011; 19(1):57-62. DOI:10.1097/MED.0b013e32834ed61f · 3.77 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To estimate the relative risk of incident cancer diagnosis among patients with juvenile idiopathic arthritis (JIA) compared to patients without JIA. A cohort of biologics-naive patients diagnosed with JIA between 1998 and 2007 and a matched cohort of comparators without JIA were assembled from the PharMetrics Patient-Centric Database. The primary outcome was any incident malignancy, excluding nonmelanoma skin cancer and carcinoma in situ. Claims profiles of patients with any cancer-related diagnosis codes were reviewed to determine outcomes. Incidence rates and 95% confidence intervals (95% CIs) of cancer were calculated and compared between cohorts using Cox proportional hazards regression. Standardized incidence ratios (SIRs) for each cohort compared to the general population were calculated using reference rates from the US Surveillance, Epidemiology, and End-Results (SEER) program. The JIA and non-JIA cohorts included 3,605 and 37,689 patients, respectively, with a mean age of 11 years. The incidence rates of cancer were 67.0 (95% CI 1.3-132.5) cases/100,000 person-years (PY) for JIA and 23.2 (95% CI 12.2-34.2) cases/100,000 PY for non-JIA. The risk of cancer associated with biologics-naive JIA was elevated (hazard ratio 2.8, 95% CI 0.9-8.3). The JIA cohort had a significantly elevated SIR of 4.0 (95% CI 2.6-6.0); the non-JIA cohort SIR was not significantly above SEER rates (SIR 1.4, 95% CI 0.6-2.6). We found a nearly 3-fold increased risk of cancer in biologics-naive JIA patients, which approached significance despite the small number of outcomes. This finding suggests an elevated underlying risk of cancer in this disease population.
    09/2012; 64(9):1357-64. DOI:10.1002/acr.21709
  • [Show abstract] [Hide abstract]
    ABSTRACT: The demonstration of the quantitative prevalence of specific cytokines in JIA formed the basis for the introduction of biological anticytokine drugs to treatment. Routine assessment of the concentration of these cytokines in blood serum may enable earlier decision making on the legitimacy of biological treatment (anti-TNF). The aim of the study was to assess the diagnostic value of TNFalpha, IL-6, and IL-1beta in monitoring the course of the disease and effectiveness of treatment with etanercept of children with oligo- and polyarticular JIA.
    Clinical laboratory 01/2014; 60(9):1481-90. DOI:10.7754/Clin.Lab.2013.130734 · 1.08 Impact Factor
Show more